Crinetics announces new data from its program evaluating PALSONIFY

Crinetics (CRNX) Pharmaceuticals announced new data from its clinical development program evaluating once-daily, oral investigational PALSONIFY in acromegaly will be presented in several oral and poster presentations at the Endocrine Society’s Annual Meeting, ENDO 2025. Notably, open-label extension data from both the pivotal PATHFNDR-1 and PATHFNDR-2 trials will be featured in two presentations, showing the long-term clinical profile of PALSONIFY in people with acromegaly. Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies. Additional PALSONIFY presentations demonstrate reductions in patient-reported symptom burden, including both symptom severity and rates of symptom flares.